Positive Interim Data of BellaSeno's Clinical Trial with Resorbable Breast and Chest Implants Reported at RACS 2023
The results were presented at the 91st Annual Scientific Congress 2023 of the Royal Australasian College of Surgeons (RACS) .
- The results were presented at the 91st Annual Scientific Congress 2023 of the Royal Australasian College of Surgeons (RACS) .
- Michael Wagels, Principal Investigator of the first clinical trial evaluating BellaSeno's implant with autologous fat grafting for pectus excavatum camouflage, reported 3-year data from the first in-human case.
- Not only was the implant safe and well tolerated, but histologic studies demonstrated tissue growth and vascularization within the implant scaffold.
- Wagels also presented animal data from large 450 ccm scaffolds showing that tissue was fully regenerated in this large volume without the development of necrosis.